Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
A single-center, investigator-initiated, single arm interventional study in patients
undergoing transfemoral transcatheter aortic valve replacement (TAVR) in the Erasmus Medical
Center in Rotterdam (NL). Study population will be patients undergoing TAVR with no formal
indication for oral anticoagulant (OAC) and no dual antiplatelet therapy (DAPT) requirement
for coronary stents. Primary endpoint is the incidence of leaflet thickening on MSCT after
three months of edoxaban treatment.